A STUDY OF THE EFFECTIVENESS OF A CARCINOSTATIC AND INCREASING GARCINOSTATIC TOLERANCE

化疗耐药在药理学上可分为基于膜的耐药和基于酶的耐药。人们对这些耐药现象进行了研究，并开发了新的治疗药物，但结果并不完全令人满意。一些药物由于其治疗效果而经常使用，但最终出现耐药性需要使用多种药物并努力应对多种不良影响。因此，也进行了研究，通过联合使用抗肿瘤和非抗肿瘤药物来克服耐药性。如果在抗肿瘤药物遇到耐药性之前抑制耐药性或延缓耐药性的发展，而不是研究已经产生耐药性的癌症，那么治疗方式可能会产生更有效的结果。我们的研究就是基于这个观点。在本研究中，我们研究了更多的抗肿瘤药物和非抗肿瘤药物。我们成功地通过免疫家兔制备了抗阿霉素的抗体。通过使用这种针对抗肿瘤药物的抗体，我们期望有意地使已施用的抗肿瘤药物活性失活，从而实现更有效的化疗。在动物实验中，我们观察到抗肿瘤剂的作用明显增强。此外，这种设计的失活能够减少抗肿瘤药物的不良影响。与ADM相关的最突出的不良反应是心脏毒性，通过联合使用抗阿德里亚霉素抗体，允许使用更大剂量的抗肿瘤药物，可以改善心脏毒性。(1)利用ADM制备抗体，所得抗ADM抗体为分子量为150000的多克隆IgG抗体，对ADM具有特异性。(2)尽管在细胞膜和辅酶q10中存在ADM等泛醌环，但抗ADM抗体对ADM缺乏交叉反应性和特异性。(3)利用抗ADM抗体，免疫组化观察ADM在癌组织中的定位。(4)癌组织细胞膜碳水化合物链抗原的变化及定位研究。(5)抗ADM抗体对ADM药理作用失活的研究报告。(6)大鼠反复给药抗adm抗体。确认抗体治疗移植肿瘤的疗效。少

Background of the studyDrug resistance in chemotherapy can be pharmacologically classified into one based on membrane resistance and another based on enzyme resistance . Studies have been conducted to elucidate these resistance phenomena and develop new therapeutic agents but the outcomes are not yet totally satisfactory. Some drugs are employed frequently due to their therapeutic efficacy but the eventual emergence of resistance necessitates the use of multiple agents and efforts to confront the multiple adverse affects. Thus studies have also been conducted to overcome resistance by the combined use of both antineoplastic and non-antineoplastic agents. A more effective outcome may be expected from the therapeutic modality if resistance is suppressed or its development delayd before the antineoplastic agents meet resistance, rather than investigating cancer that has already developed resistance. Our study was based on this viewpoint.Process and outcome of the studyIn this study, we us … More ed antineoplastic and non-antineoplastic agents. We succeeded in preparing an antibody by immunizing rabbits against ADM (adriamycin). By using this antibody directed against the antineoplastic agent, we expected to inactivate intentionally the activity of the antineoplastic agent that has been administered, thus achieving a more effective chemotherapy. In animal experiments, we observed evident potentiation of the effect of the antineoplastic agent. Furthermore this designed inactivation enabled rerductions in the adverse effects of the antineoplastic agent. The most out-standing adverse effect related to ADM is cardiotoxicity, which was amelioratedby the combined use of anti-adria-mycin antibody, permitting administration of a greater dosage of the antineoplastic agent.(1) Preparation of an antibody by using ADM.The resultant anti-ADM antibody is a polyclonal IgG antibody with a molecular weight of 150,000, which has a specificity to ADM.(2) A lack of cross reactivity and the specificity of the reaction of the anti-ADM antibody to ADM, in spite of the presence of the ubiquinone rings, such as that of ADM, in the cell membrane and Co-Q10.(3) Immunohistochemical observation of the localization of ADM in the cancerous tissue, by using the anti-ADM antibody.(4) A study on changes and localization of carbohydrate chain antigens in the cell membrane of cancerous tissue.(5) Report on the research on inactivation of the pharmacological action of ADM by the anti-ADM antibody.(6) Repeated administration of the anti-ADM antibody to rats. Confirmation of the efficacy of the antibodies in the treatment of transplanted neoplasms. Less